Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

Hypertension Clinical Trial

Official title:

Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00849810
• Other study ID #: 2009-0002
• Status: Terminated
• Phase: N/A
• First received: February 2, 2009
• Last updated: March 18, 2013
• Start date: January 2009
• Est. completion date: November 2010

Study information

• Verified date: March 2013
• Source: University of Mississippi Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to compare the effects of nebivolol and metoprolol on 24-hour ambulatory blood pressure characteristics and basal metabolic rates in patients with hypertension.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years old or older

• currently be treated at a University of MS Medical Center Internal Medicine Clinics

• currently taking metoprolol succinate for hypertension

• have their hypertension controlled (<140/90).

Exclusion Criteria:

• uncontrolled hypertension

• severe renal or moderate hepatic impairment

• currently taking CYP 2D6 inducers/inhibitors

• recent stroke (less than 6 months)

• recent myocardial infarction (less than 6 months)

• congestive heart failure

• diagnosed obstructive sleep apnea

• atrial fibrillation

• arm circumference >50 cm

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• Metoprolol
Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
• Nebivolol
5 - 20 mg daily, at a stable dose for 4 to 5 weeks

Locations

Country	Name	City	State
United States	University of Mississippi Medical Center	Jackson	Mississippi

Sponsors (1)

Lead Sponsor	Collaborator
University of Mississippi Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Outcome is Pre- and Post-treatment Ambulatory Blood Pressure.		4 weeks (pre- and post-treatment)	Yes